|
1
|
Norouzi-Barough L, Sarookhani MR, Sharifi
M, Moghbelinejad S, Jangjoo S and Salehi R: Molecular mechanisms of
drug resistance in ovarian cancer. J Cell Physiol. 233:4546–4562.
2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Wang H, Xu T, Zheng L and Li G:
Angiogenesis inhibitors for the treatment of ovarian cancer: An
updated systematic review and meta-analysis of randomized
controlled trials. Int J Gynecol Cancer. 28:903–914.
2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Hirte HW: Profile of erlotinib and its
potential in the treatment of advanced ovarian carcinoma. Onco
Targets Ther. 6:427–435. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Du Bois A and Pfisterer J: Future options
for first-line therapy of advanced ovarian cancer. Int J Gynecol
Cancer. (Suppl 1):S42–S50. 2005.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Torre LA, Trabert B, DeSantis CE, Miller
KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A and Siegel RL:
Ovarian cancer statistics, 2018. CA Cancer J Clin. 68:284–296.
2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Sato S and Itamochi H: Neoadjuvant
chemotherapy in advanced ovarian cancer: Latest results and place
in therapy. Ther Adv Med Oncol. 6:293–304. 2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Bhawal UK, Sato F, Arakawa Y, Fujimoto K,
Kawamoto T, Tanimoto K, Ito Y, Sasahira T, Sakurai T, Kobayashi M,
et al: Basic Helix-loop-helix transcription factor DEC1 negatively
regulates cyclin D1. J Pathol. 224:420–429. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kato Y, Kawamoto T, Fujimoto K and Noshiro
M: DEC1/STRA13/SHARP2 and DEC2/SHARP1 coordinate physiological
processes, including circadian rhythms in response to environmental
stimuli. Curr Top Dev Biol. 110:339–372. 2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Miyazaki K, Miyazaki M, Guo Y, Yamasaki N,
Kanno M, Honda Z, Oda H, Kawamoto H and Honda H: The role of the
basic Helix-loop-helix transcription factor Dec1 in the regulatory
T cells. J Immunol. 185:7330–7339. 2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Liu Y, Wang L, Lin XY, Wang J, Yu JH, Miao
Y and Wang EH: The transcription factor DEC1
(BHLHE40/STRA13/SHARP-2) is negatively associated with TNM stage in
non-small-cell lung cancer and inhibits the proliferation through
cyclin D1 in A549 and BE1 cells. Tumour Biol. 34:1641–1650.
2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Xu Q, Ma P, Hu C, Chen L, Xue L, Wang Z,
Liu M, Zhu H, Xu N and Lu N: Overexpression of the DEC1 protein
induces senescence in vitro and is related to better survival in
esophageal squamous cell carcinoma. PLoS One.
7(e41862)2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jia Y, Hu R, Li P, Zheng Y, Wang Y and Ma
X: DEC1 is required for anti-apoptotic activity of gastric cancer
cells under hypoxia by promoting Survivin expression. Gastric
Cancer. 21:632–642. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Murakami K, Wu Y, Imaizumi T, Aoki Y, Liu
Q, Yan X, Seino H, Yoshizawa T, Morohashi S, Kato Y and Kijima H:
DEC1 promotes hypoxia-induced epithelial-mesenchymal transition
(EMT) in human hepatocellular carcinoma cells. Biomed Res.
38:221–227. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bi H, Li S, Qu X, Wang M, Bai X, Xu Z, Ao
X, Jia Z, Jiang X, Yang Y and Wu H: DEC1 regulates breast cancer
cell proliferation by stabilizing cyclin E protein and delays the
progression of cell cycle S phase. Cell Death Dis.
6(e1891)2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hu J, Mao Z, He S, Zhan Y, Ning R, Liu W,
Yan B and Yang J: Icariin protects against glucocorticoid induced
osteoporosis, increases the expression of the bone enhancer DEC1
and modulates the PI3K/Akt/GSK3β/β-catenin integrated signaling
pathway. Biochem Pharmacol. 136:109–121. 2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhu Z, Wang YW, Ge DH, Lu M, Liu W, Xiong
J, Hu G, Li XP and Yang J: Downregulation of DEC1 contributes to
the neurotoxicity induced by MPP(+) by suppressing PI3K/Akt/GSK3β
pathway. CNS Neurosci Ther. 23:736–747. 2017.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Shi J, Zhu Q, Wu J and Zhu P: FAM46C
suppresses gastric cancer by inhibition of Wnt/beta-catenin. Front
Biosci (Landmark Ed). 25:549–563. 2020.PubMed/NCBI
|
|
20
|
Zhang C, Zhang Z, Zhang S, Wang W and Hu
P: Targeting of Wnt/β-catenin by anthelmintic drug pyrvinium
enhances sensitivity of ovarian cancer cells to chemotherapy. Med
Sci Monit. 23:266–275. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Hu Z, Wang P, Lin J, Zheng X, Yang F,
Zhang G, Chen D, Xie J, Gao Z, Peng L and Xie C: MicroRNA-197
Promotes metastasis of hepatocellular carcinoma by activating
wnt/β-catenin signaling. Cell Physiol Biochem. 51:470–486.
2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kumar R, Kotapalli V, Naz A, Gowrishankar
S, Rao S, Pollack JR and Bashyam MD: XPNPEP3 is a novel
transcriptional target of canonical Wnt/β-catenin signaling. Genes
Chromosomes Cancer. 57:304–310. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wang Y, Lei L, Zheng YW, Zhang L, Li ZH,
Shen HY, Jiang GY, Zhang XP, Wang EH and Xu HT: Odd-skipped related
1 inhibits lung cancer proliferation and invasion by reducing Wnt
signaling through the suppression of SOX9 and β-catenin. Cancer
Sci. 109:1799–1810. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Raghavan S, Mehta P, Xie Y, Lei YL and
Mehta G: Ovarian cancer stem cells and macrophages reciprocally
interact through the WNT pathway to promote pro-tumoral and
malignant phenotypes in 3D engineered microenvironments. J
Immunother Cancer. 7(190)2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kim MS, Cho HI, Yoon HJ, Ahn YH, Park EJ,
Jin YH and Jang YK: JIB-04, A Small molecule histone demethylase
inhibitor, selectively targets colorectal cancer stem cells by
inhibiting the wnt/β-catenin signaling pathway. Sci Rep.
8(6611)2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Zhou L, Rui JA, Ye DX, Wang SB, Chen SG
and Qu Q: Edmondson-Steiner grading increases the predictive
efficiency of TNM staging for long-term survival of patients with
hepatocellular carcinoma after curative resection. World J Surg.
32:1748–1756. 2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zhou J, Du Y, Lu Y, Luan B, Xu C, Yu Y and
Zhao H: CD44 expression predicts prognosis of ovarian cancer
patients through promoting Epithelial-mesenchymal transition (EMT)
by regulating snail, ZEB1, and caveolin-1. Front Oncol.
9(802)2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Gonçalves V, Pereira JFS and Jordan P:
Signaling pathways driving aberrant splicing in cancer cells. Genes
(Basel). 9(9)2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Arend RC, Londoño-Joshi AI, Straughn JM Jr
and Buchsbaum DJ: The Wnt/β-catenin pathway in ovarian cancer: A
review. Gynecol Oncol. 131:772–779. 2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yeung TL, Leung CS, Yip KP, Au Yeung CL,
Wong ST and Mok SC: Cellular and molecular processes in ovarian
cancer metastasis. A review in the theme: Cell and molecular
processes in cancer metastasis. Am J Physiol Cell Physiol.
309:C444–C456. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Grunewald T and Ledermann JA: Targeted
therapies for ovarian cancer. Best Pract Res Clin Obstet Gynaecol.
41:139–152. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kroeger PT Jr and Drapkin R: Pathogenesis
and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol.
29:26–34. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kaldawy A, Segev Y, Lavie O, Auslender R,
Sopik V and Narod SA: Low-grade serous ovarian cancer: A review.
Gynecol Oncol. 143:433–438. 2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Liu Y, Miao Y, Wang J, Lin X, Wang L, Xu
HT and Wang EH: DEC1 is positively associated with the malignant
phenotype of invasive breast cancers and negatively correlated with
the expression of claudin-1. Int J Mol Med. 31:855–860.
2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
You J, Lin L, Liu Q, Zhu T, Xia K and Su
T: The correlation between the expression of differentiated
embryo-chondrocyte expressed gene l and oral squamous cell
carcinoma. Eur J Med Res. 19(21)2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Yan Z, Shi X, Min W, Jia Y, Li B, Zhang Y,
Liu Q and Wang Y: The increased expression of DEC1 gene is related
to HIF-1α protein in gastric cancer cell lines. Mol Biol Rep.
39:4229–4236. 2012.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Czekierdowska S, Stachowicz N, Chróściel M
and Czekierdowski A: Proliferation and maturation of intratumoral
blood vessels in women with malignant ovarian tumors assessed with
cancer stem cells marker nestin and platelet derived growth factor
PDGF-B. Ginekol Pol. 88:120–128. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wei ZT, Zhang X, Wang XY, Gao F, Zhou CJ,
Zhu FL, Wang Q, Gao Q, Ma CH, Sun WS, et al: PDCD4 inhibits the
malignant phenotype of ovarian cancer cells. Cancer Sci.
100:1408–1413. 2009.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Zuo K, Zhao Y, Zheng Y, Chen D, Liu X, Du
S and Liu Q: Long non-coding RNA XIST promotes malignant behavior
of epithelial ovarian cancer. Onco Targets Ther. 12:7261–7267.
2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Yu HL, Ma XD, Tong JF, Li JQ, Guan XJ and
Yang JH: WTAP is a prognostic marker of high-grade serous ovarian
cancer and regulates the progression of ovarian cancer cells. Onco
Targets Ther. 12:6191–6201. 2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Twomey C and Mccarthy JV: Pathways of
apoptosis and importance in development. J Cell Mol Med. 9:345–359.
2010.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Li Y, Zhang H, Xie M, Hu M, Ge S, Yang D,
Wan Y and Yan B: Abundant expression of Dec1/stra13/sharp2 in colon
carcinoma: Its antagonizing role in serum deprivation-induced
apoptosis and selective inhibition of procaspase activation.
Biochem J. 367:413–422. 2002.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Liu Y, Ren CC, Yang L, Xu YM and Chen YN:
Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and
CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration
and invasion in vitro. J Cell Physiol. 234:3897–3909.
2019.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Al Ameri W, Ahmed I, Al-Dasim FM, Ali
Mohamoud Y, Al-Azwani IK, Malek JA and Karedath T: Cell
type-specific TGF-β mediated EMT in 3D and 2D models and its
reversal by TGF-β receptor kinase inhibitor in ovarian cancer cell
lines. Int J Mol Sci. 20(3568)2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Zhang H, Wang Y, Chen T, Zhang Y, Xu R,
Wang W, Cheng M and Chen Q: Aberrant activation of hedgehog
signalling promotes cell migration and invasion via matrix
metalloproteinase-7 in ovarian cancer cells. J Cancer. 10:990–1003.
2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Wu Y, Sato F, Yamada T, Bhawal UK,
Kawamoto T, Fujimoto K, Noshiro M, Seino H, Morohashi S, Hakamada
K, et al: The BHLH transcription factor DEC1 plays an important
role in the epithelial-mesenchymal transition of pancreatic cancer.
Int J Oncol. 41:1337–1346. 2012.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Duan H, Yan Z, Chen W, Wu Y, Han J, Guo H
and Qiao J: TET1 inhibits EMT of ovarian cancer cells through
activating Wnt/β-catenin signaling inhibitors DKK1 and SFRP2.
Gynecol Oncol. 147:408–417. 2017.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Felipe Lima J, Nofech-Mozes S, Bayani J
and Bartlett JM: EMT in breast carcinoma-a review. J Clin Med.
5(65)2016.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Chen Y, Wang DD, Wu YP, Su D, Zhou TY, Gai
RH, Fu YY, Zheng L, He QJ, Zhu H and Yang B: MDM2 promotes
epithelial-mesenchymal transition and metastasis of ovarian cancer
SKOV3 cells. Br J Cancer. 117:1192–1201. 2017.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Walston T, Tuskey C, Edgar L, Hawkins N,
Ellis G, Bowerman B, Wood W and Hardin J: Multiple Wnt signaling
pathways converge to orient the mitotic spindle in early C.
elegans embryos. Dev Cell. 7:831–841. 2004.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Yang S, Liu Y, Li MY, Ng CSH, Yang SL,
Wang S, Zou C, Dong Y, Du J, Long X, et al: FOXP3 promotes tumor
growth and metastasis by activating Wnt/β-catenin signaling pathway
and EMT in non-small cell lung cancer. Mol Cancer.
16(124)2017.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Wang H, Wu M, Lu Y, He K, Cai X, Yu X, Lu
J and Teng L: LncRNA MIR4435-2HG targets desmoplakin and promotes
growth and metastasis of gastric cancer by activating Wnt/β-catenin
signaling. Aging (Albany NY). 11:6657–6673. 2019.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Smolders LA, Meij BP, Riemers FM, Licht R,
Wubbolts R, Heuvel D, Grinwis GC, Vernooij HC, Hazewinkel HA,
Penning LC and Tryfonidou MA: Canonical Wnt signaling in the
notochordal cell is upregulated in early intervertebral disk
degeneration. J Orthop Res. 30:950–957. 2012.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Rask K, Nilsson A, Brännström M, Carlsson
P, Hellberg P, Janson PO, Hedin L and Sundfeldt K: Wnt-signalling
pathway in ovarian epithelial tumours: Increased expression of
beta-catenin and GSK3beta. Br J Cancer. 89:1298–1304.
2003.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Li J, Yin J, Shen W, Gao R, Liu Y, Chen Y,
Li X, Liu C, Xiang R and Luo N: TLR4 promotes breast cancer
metastasis via Akt/GSK3β/β-catenin pathway upon LPS stimulation.
Anat Rec (Hoboken). 300:1219–1229. 2017.PubMed/NCBI View Article : Google Scholar
|
